ALB and hepatocellular carcinoma: In our cohort, MELD 3.0 performed better than classical MELD and MELD-Na, likely because of the incorporation of albumin and sex into its calculation [76].While still inferior to albumin and CRP/albumin ratio, this finding suggests that MELD 3.0 may offer better risk stratification in patients with MASLD- and ALD-related HCC and warrants further validation in larger, external cohorts.